

H<sub>2</sub>O WORLD 2 0 1 7


a 2017

Healthcare and Life Sciences


Use-Case Retrospective

**Sanjay Joshi** 





Knowledge Soup Source: http://www.jfsowa.com/talks/iccs03.htm



## Clinical Knowledge Soup



# USE-CASES ☐ Financial □ Operational ☐ Clinical Imaging



# FINANCIAL



**Hospital Readmissions** 



Patient Satisfaction



Physician, Nurse Burn-Out



Market Analysis




Patient Stratification



Physician, Nurse Calendar

#### Claims, Risk



Source: Brinkmann P, InsuranceERM Summer 2013



# OPERATIONAL





**Patient** Satisfaction



**Rx Medication** Reconciliation

**Patient** 

**Stratification** 



Regulatory





**Patient** Registries



CCD **Clinical Notes** 




**Determinants** 



**Prospective** Randomized




Retrospective



Cluster **Randomized** 



N-of-1




Basket, **Umbrella** 






# CLINICAL



Derived from: Paul Fishbeck, Carnegie Mellon University, Research Report, 2009; CBO, 2013

Type of Care, Annualized % Change in Spending



5.92 (4.85 to 6.9)

8.11 (6.57 to 9.97)

2.88 (1.83 to 4.15)

5.93 (5.1 to 6.69)

9.56 (8.09 to 11.32

4.38 (3.1 to 5.71)

Age Group, %

.88 (3.27 to 6.91

.11 (-0.18 to 2.53)

			Type of Care, Annualized to Change in Spending					Age droup, 70		
	Total Change, 1996-2013, \$ Billions	Total Annualized % Change in Spending	Ambulatory	Inpatient	Prescribed Retail Pharmaceuticals	Nursing Facility Care	Emergency Care	0-19 y	20-64 y	≥65 y
All causes	933.53 (933.52 to 933.53)	3.52 (3.52 to 3.52)	3.69 (3.69 to 3.69)	2.77 (2.77 to 2.77)	5.64 (5.64 to 5.64)	2.5 (2.5 to 2.5)	6.42 (6.42 to 6.42)	2.65 (2.4 to 2.89)	3.64 (3.58 to 3.7)	3.63 (3.55 to 3.72)
Diabetes	64.43 (57.88 to 70.61)	6.13 (5.29 to 6.95)	5.03 (3.63 to 6.49)	4.32 (3.28 to 5.82)	8.85 (7.14 to 10.62)	0.99 (0.26 to 1.51)	5.25 (3.22 to 7.48)	3.5 (2.55 to 4.48)	6.68 (5. 73 to 7.67)	5.6 (4.87 to 6.43)
Low back and neck pain	57.2 (47.38 to 64.4)	6.47 (5.25 to 7.74)	5.53 (3.89 to 7.24)	8.52 (7.14 to 9.59)	8.12 (6 to 10.16)	6.42 (5.18 to 7.81)	8.62 (6.73 to 10.55)	3.03 (1.67 to 4.5)	5.84 (4.57 to 7.16)	8.8 (7.7 to 9.94)
Hypertension <sup>a</sup>	47.59 (41.7 to 53.73)	5.06 (4.2 to 5.93)	6.92 (5.6 to 8.32)	5.24 (3.06 to 7.05)	4.77 (3.24 to 6.44)	0.71 (-0.18 to 1.25)	9.39 (7.25 to 11.66)	1.38 (0.08 to 2.41)	5.09 (4. 07 to 6.1)	5.1 (4.26 to 5.97)
Hyperlipidemia <sup>a</sup>	41.94 (37.7 to 45.37)	10.28 (8.87 to 11.62)	10.27 (8.57 to 11.95)	3.26 (0.8 to 4.92)	10.42 (8.73 to 12.1)	3.9 (1.75 to 7.13)	4.01 (3.41 to 4.54)	1.76 (-1.7 to 6.58)	9.13 (7.74 to 10.56)	11.97 (10.44 to 13.6
Depressive disorders	30.83 (25.33 to 36.79)	3.41 (2.76 to 4.08)	3.62 (2.74 to 4.63)	-1.32 (-1.87 to -0.77)	6.84 (4.86 to 8.92)	0.87 (0.11 to 1.51)	7.02 (4.15 to 10.16)	2.7 (1.78 to 3.56)	3.68 (2.98 to 4.43)	2.34 (1.56 to 3.05)
Falls	30.4 (24.12 to 36.89)	3.04 (2.4 to 3.72)	4.39 (2.68 to 6.13)	1.81 (0.71 to 3.01)	0.57 (-1.56 to 2.72)	-0.06 (-1.15 to 1.2)	7.18 (5.89 to 8.61)	3.33 (2.34 to 4.43)	3.68 (2.69 to 4.57)	2.48 (1.84 to 3.32)
Urinary diseases	30.16 (25.84 to 35.29)	4.81 (4 to 5.73)	2.9 (1.45 to 4.37)	3.69 (2.67 to 5.19)	5.39 (3.23 to 7.76)	10.11 (8.75 to 11.59)	9.52 (7.62 to 11.36)	1.86 (0.83 to 2.93)	3.72 (2.83 to 4.66)	6.38 (5.52 to 7.32)

3.75 (1.49 to 6.57)

2.56 (~11.14 to 6.79

0.69 (-1.46 to 3.55)

#### Source:

Osteoarthritis

Oral disorders

Septicemia

Dieleman JL, et al, "Factors Associated With Increases in US Health Care Spending, 1996-2013" JAMA. Nov 2017; 318(17):1668-1678. doi:10.1001/jama.2017.15927

7.69 (6.36 to 8.69)

9.23 (7.68 to 11.08)

4.3 (2.84 to 6.72)

## Highest 18yr Cost Increase:

5.92 (5.12 to 6.72)

8.91 (7.43 to 10.66)

2.88 (1.83 to 4.15)

5.42 (3.69 to 7.16)

-0.38 (-1.86 to 1.17)

1.47 (-0.31 to 3.43)

29.86 (25.78 to 33.65)

25.95 (20.02 to 33.71)

25.25 (17.42 to 33.16)

1. Hyperlipidemia

0.22 (-0.58 to 0.74)

3.97 (2.52 to 5.07)

1.44 (-0.09 to 4.69)

4.15 (-0.37 to 7.73)

3.81 (2.47 to 4.97)

- 2. Septicemia
- 3. Pain
- 4. Diabetes
- 5. Osteoarthritis



#### Dysbiosis Homeostasis inflammatory SCFA SCFA factors Bile acids Adipose Tissue **Pancreas** Liver Gut Adipose inflammation Insulin response Insulin response Gluconeogensis GLP-1, PYY

#### Source:

Suze J. et al, "Role of the microbiome in the normal and aberrant glycemic response", Clinical Nutrition Experimental 6 (2016) 59-73

Balanced glycemic response

(pathways)

time-series (loT + microbiome?)











ocorventis

BASIS



COSMOSO


О-€РЕПОМЕ

Biomedical sensor landscape

Derived from: Google Life Sciences, Rock Health,

### Al on the Edge





Source: Goh C and Kinght JC, "Enhanced understanding of the host-pathogen interaction in sepsis: new opportunities for omic approaches", The Lancet Respiratory Medicine, Volume 5, No. 3, p212-223, March 2017

## **SEPTICEMIA**

(NEWS + comorbid.)

time-series (microbiome?)

#### Observation chart for the National Early Warning Score (NEWS) 0 1 2 3 ADMISSION DATE: D.O.B. DATE DATE TIME TIME 21-24 RESP. 12-20 12-20 RATE Sp0<sub>2</sub> 94-95 92-93 2 92-93 3 Inspired 0:% TEMP 200 NEW SCORE 160 ıses Systolic BLOOD PRESSURE 100 HEART Level of Consciousnes V/P/U BLOOD SUGAR Bl'd Sugar TOTAL

Source:

TOTAL NEW SCORE

p

h

e

n

0

e

Royal College of Physicians, "National Early Warning Score (NEWS): Standardising the assessment of acuteillness severity in the NHS.", Report of a working party. London: RCP, July 2012.

H,O

#### PAIN ASSESSMENT GUIDE

#### TELL ME ABOUT YOUR PAIN

## W.

#### ords to describe pain

aching stabbing tender tiring numb dull crampy throbbing gnawing burning penetrating miserable

radiating

shooting sharp exhausting nagging unbearable squeezing pressure

#### Pain in other languages

deep

itami tong dau Japanese Chinese Vietnamese dolor douleur bolno Spanish French Russian

ntensity (0-10)

If 0 is no pain and 10 is the worst pain imaginable, what is your pain now? ... in the last 24 hours?

cation

Where is your pain?

**D**uration

Is the pain always there?

Does the pain come and go? (Breakthrough Pain)

Do you have both types of pain?


aggravating and Alleviating Factors
What makes the pain better?

What makes the pain better? What makes the pain worse?

## PAIN

#### UNIVERSAL PAIN ASSESSMENT TOOL

This pain assessment tool is intended to help patient care providers assess pain according to individual patient needs. Explain and use 0-10 Scale for patient self-assessment. Use the faces or behavioral observations to interpret expressed pain when patient cannot communicate his/her pain intensity.




#### Sources:

Fink R, "Proceedings of Baylor Univ Med Center.", (2000 Jul); 13(3): 236–239.

Wong D, Whaley L. "Clinical Handbook of Pediatric Nursing.", 2nd ed. (1986) St. Louis, Mo: Mosby.



## Opioid Overdose and Risks



#### Sources:

The Economist, "Inside the Opioid Epidemic", May 2017 <a href="https://www.economist.com/news/united-states/21721960-deaths-drugs-say-more-about-markets-about-white-despair-inside-opioid">https://www.economist.com/news/united-states/21721960-deaths-drugs-say-more-about-markets-about-white-despair-inside-opioid</a>
Volkow ND & McLellan AT, "Opioid Abuse in Chronic Pain — Misconceptions and Mitigation Strategies", NEJM (2016); 374:1253-63. DOI: 10.1056/NEJMra1507771

# Feature Engineering + Classification + time-series. (also Fraud and Distribution)

Factor	Risk
Medication-related	
Daily dose >100 MME*	Overdose,8 addiction8
Long-acting or extended-release formulation (e.g., methadone, fentanyl patch)	Overdose <sup>14,41</sup>
Combination of opioids with benzodiazepines	Overdose <sup>42</sup>
Long-term opioid use (>3 mo)†	Overdose,43 addiction44
Period shortly after initiation of long-acting or extended-release formulation (<2 wk)	Overdose <sup>45</sup>
Patient-related	
Age >65 yr	Overdose <sup>46</sup>
Sleep-disordered breathing‡	Overdose <sup>47</sup>
Renal or hepatic impairment§	Overdose <sup>48</sup>
Depression	Overdose, addiction <sup>49</sup>
Substance-use disorder (including alcohol)	Overdose,50 addiction49
History of overdose	Overdose <sup>51</sup>
Adolescence	Addiction <sup>52</sup>




H<sub>2</sub>O.ai

# IMAGING


Source: Parmar C, et al, "Machine Learning methods for Quantitative Radiomic Biomarkers", Nature Scientific Reports, 5:13087, Aug2015

ML

\*Source: Dr. Bradley Erickson, Mayo Clinic, RSNA 2017




## **Anatomy Recognition**



Source: Yan Z, et al. "Multi-Instance Deep Learning: Discover Discriminative Local Anatomies for Bodypart Recognition." IEEE trans on medical imaging 35.5 (2016): 1332-1343

DL

## **Organ Segmentation**



Source: Roth HR, et al. "DeepOrgan: Multi-level deep convolutional networks for automated pancreas segmentation." International Conference on Medical Image Computing and Computer-Assisted Intervention. Springer, 2015.



## **Analytics Capability and Maturity Model**

Level 8	Cost per Unit of Health Reimbursement & Prescriptive Analytics
Level 7	Cost per Capita Reimbursement & Predictive Analytics
Level 6	Cost per Case Reimbursement & Data Driven Culture
Level 5	Clinical Effectiveness & Population Management
Level 4	Automated External Reporting
Level 3	Automated Internal Reporting
Level 2	Standardized Vocabulary & Patient Registries
Level 1	Data Integration – Enterprise Data Warehouse
Level 0	Fragmented Point Solutions

STAGE 7	Personalized medicine & prescriptive analytics
STAGE 6	Clinical risk intervention & predictive analytics
STAGE 5	Enhancing quality of care, population health, and understanding the economics of care
STAGE 4	Measuring & managing evidence based care, care variability, and waste reduction
STAGE 3	Efficient, consistent internal and external report production and agility

STAGE 2	Core data warehouse workout: centralized database with an analytics competency center
STAGE 1	Foundation building: data aggregation and initial data governance
STAGE 0	Fragmented point solutions



Source: HUMSS



